We’re gathering expertise from diverse industries to drive ambitious solutions to one of science’s — and nature’s — greatest challenges. Together, we can stop the next influenza pandemic before it starts.
See the steps we are taking to harness new thinking, scientific advances and technological capabilities in our pursuit of a long-lasting influenza vaccine.
Sabin-Aspen Vaccine Science & Policy Group Convenes
The Sabin-Aspen Vaccine Science & Policy Group convenes influential, out-of-the-box thinkers across scientific, medical, industry and regulatory sectors to vigorously probe a single topic each year and develop actionable recommendations. Meeting 100 years after the 1918 – 1919 influenza epidemic that killed an estimated 50 million people worldwide, the group focused its initial meeting on the urgent need for next-generation vaccines and Big Ideas for jump-starting the development of a universal influenza vaccine.
Influenzer Initiative Holds Call to Action with Vaccine Champions
The Influenzer Initiative, hosted by the Wellcome Trust, engages leaders in influenza and vaccine research, technology, industry, funding and policy to reimagine development of a UIV. Building on their insights, Sabin’s funding partner, Flu Lab, working with the Center for Open Science and the Public Library of Science, launches a platform to expand access to null and negative research results and encourage replication of influenza research findings.
Sabin-Aspen Vaccine Science & Policy Group Report Issued
Following their initial meeting, the Group releases a report communicating the urgent need for a universal influenza vaccine (UIV) and putting forward bold recommendations.
Options X Conference Spotlights Sabin-Aspen Report
The 10th Options for the Control of Influenza (Options X) conference features a conversation on the Sabin-Aspen Vaccine Science & Policy Group Report, co-hosted by Flu Lab. Representatives of biotech, industry, government, academia and philanthropy probe how the report’s “Big Ideas” around scientific collaboration, data sharing and transformative funding can be incentivized and realized.
Convergence Science Agenda
Building on recommendations of the Sabin-Aspen Vaccine Science & Policy Group, Sabin kicks off promotion of an innovation agenda to accelerate the discovery and development of next-generation influenza vaccines. A working group of forward-looking researchers, innovators and thought leaders, as well as newcomers to the influenza research space will explore and shape novel frameworks of inquiry to catalyze new discovery and innovation.
Convergence Science Agenda
We’re bringing together intellectual, investment and technology communities and expertise to accelerate development of a universal influenza vaccine.
We’ve been lucky for the last 100 years that we haven’t had a pandemic of the magnitude of 1918. If we have one soon, it will be catastrophic, because we live in a world where viruses and bacteria travel around the globe at lightning speed.Shirley Tilghman, President Emerita of the University and Professor of Molecular Biology and Public Affairs, Princeton University
To solve this enormous problem, we need to go beyond the current strategies that are being deployed and build on great advances in sciences like immunology and structural biology with new ideas from fields like computer science and physics.Bob Tepper, Co-Founder and General Partner, Third Rock Ventures, LLC
It’s absolutely essential that people from different disciplines, with different areas of expertise, come together to solve this huge problem.Penny Heaton, Chief Executive Officer, Bill & Melinda Gates Medical Research Institute
At the moment, pandemic influenza is probably near the top of every government’s risk register. We know that there will be another influenza pandemic, and that it will have a massive impact across the world.Sarah Gilbert, Professor of Vaccinology, Edward Jenner Institute for Vaccine Research, University of Oxford; Co-Founder, Vaccitech
An interdisciplinary convergent model is the most promising way to bring about significant scientific progress.Harvey Fineberg, President, Gordon and Betty Moore Foundation
The Sabin-Aspen Vaccine Science & Policy Group brings together senior leaders across many disciplines to examine some of the most challenging vaccine-related issues and drive impactful change. Members are influential, creative, out-of-the-box thinkers who vigorously probe a single topic each year and develop actionable recommendations to advance innovative ideas for the development, distribution, and use of vaccines, as well as evidence-based and cost-effective approaches to immunization.